<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929691</url>
  </required_header>
  <id_info>
    <org_study_id>CDC Foundation Award 1085.1</org_study_id>
    <nct_id>NCT04929691</nct_id>
  </id_info>
  <brief_title>The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19</brief_title>
  <acronym>CircumVent</acronym>
  <official_title>The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Using an Implementation Research Framework</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aliko Dangote Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nigerian Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CDC Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the CircumVent Project is to evaluate the feasibility, adaptability and&#xD;
      acceptability of a CPAP/O2 helmet solution for non-invasive ventilation among patients with&#xD;
      COVID-19 and health workers in eight COVID-19 treatment and isolation centers in Nigeria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory failure, a major cause of death in COVID-19, is managed with high-flow&#xD;
      oxygen therapy via invasive mechanical ventilation. In resource-limited settings like Nigeria&#xD;
      the shortage of ventilators and oxygen supply make this option challenging. Evidence-based&#xD;
      non-invasive alternatives to mechanical ventilation such as the use of continuous positive&#xD;
      airway pressure (CPAP) devices exist, but there have been concerns that non-invasive&#xD;
      ventilation may expose healthcare workers to infection from aerosolized dispersion of&#xD;
      SARS-CoV-2. The investigators propose to evaluate the feasibility, adaptability and&#xD;
      acceptability of a CPAP/O2 helmet solution for non-invasive ventilation among patients with&#xD;
      COVID-19 and health workers in eight COVID-19 treatment and isolation centers in Nigeria.&#xD;
&#xD;
      The study will occur in 4 stages: 1) Convene a Steering Committee of key stakeholders and&#xD;
      recruit implementation sites; 2) Use the integrated Promoting Action on Research&#xD;
      Implementation in Health Services (i-PARiHS) framework to guide a needs assessment of&#xD;
      treatment centers' capacity to use high-flow oxygen therapy to treat COVID-19 patients, and&#xD;
      utilize the findings to develop an implementation strategy for use of CPAP/ O2 helmet&#xD;
      solution; 3) Build infrastructure to support training and data monitoring processes and to&#xD;
      develop implementation protocols to evaluate the adaptability of the strategy for the use of&#xD;
      the CPAP/O2 helmet; and 4) Train health workers, distribute a CPAP/O2 helmet solution for&#xD;
      non-invasive ventilation, pilot test the implementation strategy, and assess feasibility of&#xD;
      its use and acceptability that includes monitoring altered risk of SARS-CoV-2 infection among&#xD;
      healthcare workers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will occur in 4 stages: 1) Convene a Steering Committee of key stakeholders and recruit implementation sites; 2) Use the integrated Promoting Action on Research Implementation in Health Services (i-PARiHS) framework to guide a needs assessment of treatment centers' capacity to use high-flow oxygen therapy to treat COVID-19 patients, and utilize the findings to develop an implementation strategy for use of CPAP/ O2 helmet solution; 3) Build infrastructure to support training and data monitoring processes and to develop implementation protocols to evaluate the adaptability of the strategy for the use of the CPAP/O2 helmet; and 4) Train health workers, distribute a CPAP/O2 helmet solution for non-invasive ventilation, pilot test the implementation strategy, and assess feasibility of its use and acceptability that includes monitoring altered risk of SARS-CoV-2 infection among healthcare workers.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>1-4 weeks while on admission</time_frame>
    <description>mild, 11-19/min; moderate, 20-24/min; severe, 25-30/min; very severe, &gt;30 or &lt;=10/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse Oximetry</measure>
    <time_frame>1-4 weeks while on admission</time_frame>
    <description>mild &gt;90; moderate &lt;=90; severe, &lt;88</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disposition</measure>
    <time_frame>1-4 weeks while on admission</time_frame>
    <description>Died; Improved; Intubated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of using CPAP/O2 helmet solution</measure>
    <time_frame>1- 4 weeks while on admission</time_frame>
    <description>Feasibility of Intervention Measure (FIM, Weiner et al. 2017), 4-item instrument with a 5-point ordinal scale (1 = minimum, 5 = maximum) that takes &lt; 5 minutes to complete. Higher scores imply better outcome (greater feasibility).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptability of the strategy for implementing CPAP/O2 helmet solution</measure>
    <time_frame>1-4 weeks while on admission</time_frame>
    <description>Qualitative description of helmet use adaptations via self-report; Observed adaptation to patient characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of CPAP/O2 helmet solution for non-invasive management of COVID-19</measure>
    <time_frame>1-4 weeks while on admission</time_frame>
    <description>Acceptability of Intervention Measure (AIM, Weiner et al. 2017), a 4-item instrument with a 5-point ordinal scale (1= minimum, 5 = maximum). Higher scores imply better outcome (greater acceptability).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>CPAP- Helmet Users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients admitted to a study site with suspected or confirmed COVID-19 and who consented to using the CPAP helmet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CPAP helmet users</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients admitted to a study site with suspected or confirmed COVID-19 but who did not use a CPAP helmet</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP helmet</intervention_name>
    <description>helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation</description>
    <arm_group_label>CPAP- Helmet Users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care non-helmet based CPAP ventilation</intervention_name>
    <description>Standard of care ventilation without helmet-based CPAP</description>
    <arm_group_label>Non-CPAP helmet users</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients admitted to a study site with respiratory distress and suspected or&#xD;
             confirmed COVID-19 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not meet eligibility criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babatunde L Salako, MBBS, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Nigerian Institute for Medical Research, Lagos, Nigeria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andre Fenton, PhD</last_name>
    <phone>+1-212-992-6573</phone>
    <email>afenton@nyu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olugbenga Ogedegbe, MD, MPH</last_name>
    <phone>+1-646-501-3435</phone>
    <email>Olugbenga.Ogedegbe@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nigerian Institute of Medical Research</name>
      <address>
        <city>Yaba</city>
        <state>Lagos</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Ezechi, MBBS, FWACS</last_name>
      <phone>+2348033065683</phone>
      <email>oezechi@nimr.gov.ng</email>
    </contact>
    <investigator>
      <last_name>Babatunde L Salako, MBBS, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal Medical Center, Abeokuta</name>
      <address>
        <city>Abeokuta</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adenike Odewabi, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alex Ekwueme Federal University Teaching Hospital</name>
      <address>
        <city>Enugu</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeoma Ulasi, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Enugu State University Teaching Hospital</name>
      <address>
        <city>Enugu</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeoma Ulasi, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel O Ajayi, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aminu Kano Teaching Hospital</name>
      <address>
        <city>Kano</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliyu Abdu, MBBS, FMCP</last_name>
    </contact>
    <contact_backup>
      <last_name>Baba M Musa, MBBS, FRCP</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Federal Medical Center, Ebute Metta</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adedamola Dada, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lagos University Teaching Hospital</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muyiwa Rotimi, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delta State University Teaching Hospital</name>
      <address>
        <city>Oghara</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Onome Ogueh, MBBS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <link>
    <url>https://www.circumventproject.com/</url>
    <description>Circumvent Project homepage</description>
  </link>
  <reference>
    <citation>Patel BK, Wolfe KS, MacKenzie EL, Salem D, Esbrook CL, Pawlik AJ, Stulberg M, Kemple C, Teele M, Zeleny E, Macleod J, Pohlman AS, Hall JB, Kress JP. One-Year Outcomes in Patients With Acute Respiratory Distress Syndrome Enrolled in a Randomized Clinical Trial of Helmet Versus Facemask Noninvasive Ventilation. Crit Care Med. 2018 Jul;46(7):1078-1084. doi: 10.1097/CCM.0000000000003124.</citation>
    <PMID>29595563</PMID>
  </reference>
  <reference>
    <citation>Liu Q, Gao Y, Chen R, Cheng Z. Noninvasive ventilation with helmet versus control strategy in patients with acute respiratory failure: a systematic review and meta-analysis of controlled studies. Crit Care. 2016 Aug 23;20:265. doi: 10.1186/s13054-016-1449-4. Review.</citation>
    <PMID>27549178</PMID>
  </reference>
  <reference>
    <citation>Beitler JR, Owens RL, Malhotra A. Unmasking a Role for Noninvasive Ventilation in Early Acute Respiratory Distress Syndrome. JAMA. 2016 Jun 14;315(22):2401-3. doi: 10.1001/jama.2016.5987.</citation>
    <PMID>27179463</PMID>
  </reference>
  <reference>
    <citation>Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, Ferrari G, Corradi F, Pelosi P, Bignamini A, Tarsia P, Cosentini R. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med. 2014 Jul;40(7):942-9. doi: 10.1007/s00134-014-3325-5. Epub 2014 May 10. Erratum in: Intensive Care Med. 2014 Aug;40(8):1187.</citation>
    <PMID>24817030</PMID>
  </reference>
  <reference>
    <citation>Chiumello D, Brochard L, Marini JJ, Slutsky AS, Mancebo J, Ranieri VM, Thompson BT, Papazian L, Schultz MJ, Amato M, Gattinoni L, Mercat A, Pesenti A, Talmor D, Vincent JL. Respiratory support in patients with acute respiratory distress syndrome: an expert opinion. Crit Care. 2017 Sep 12;21(1):240. doi: 10.1186/s13054-017-1820-0. Review.</citation>
    <PMID>28899408</PMID>
  </reference>
  <reference>
    <citation>Delclaux C, L'Her E, Alberti C, Mancebo J, Abroug F, Conti G, Guérin C, Schortgen F, Lefort Y, Antonelli M, Lepage E, Lemaire F, Brochard L. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: A randomized controlled trial. JAMA. 2000 Nov 8;284(18):2352-60.</citation>
    <PMID>11066186</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-invasive ventilation</keyword>
  <keyword>implementation science</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Any study data to be shared will need to conform to Nigeria national data regulations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

